NAD+(1000 mg)
Restores the cell-energy coenzyme that halves between age 20 and 50.
$89
Why researchers choose it
SS-31 targets the cell's power plants directly, tucking into the mitochondrial membrane where energy is made. In September 2025 it became the first mitochondria-targeted drug the FDA has ever approved (as Forzinity, for a rare disease). Everything beyond that one approval, including the longevity interest, is still research.
Reconstitution reference concentration only, not dosing
Set the vial strength and how much bacteriostatic water you draw into it. This returns the resulting concentration for lab handling. It is a dilution reference, not a dosing recommendation.
—mg / mL
Each 0.01 mL — one unit on a U-100 syringe — holds —
| Syringe draw | Volume | Amount in that volume |
|---|
Most compounds reconstitute with bacteriostatic water; a few acid-loving peptides use acetic acid instead. How much to draw, and how many vials a cycle needs, live in the Complete Peptide Guide, not here.
How much, and how many vials for a full cycle?
Protocol and cycle-length questions get answered in the Complete Peptide Guide, not here. These listings carry no dosing.